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Roles of RhoA, RhoC and RhoG in Secretion of Vascular 
Endothelial Growth Factor (VEGF) by Astrocytoma Cells and 
Angiogenesis in Vascular Endothelial Cells 
 
Amira Khalil Fakih 
 
ABSTRACT 
 
As the tumor size increases, cancer cells stimulate neighboring vascular endothelial cells 
to proliferate and form new blood vessels in order to irrigate the tumor. This is through 
the secretion of vascular endothelial growth factors (VEGF) by the cancer cells that 
stimulate angiogenesis in vascular endothelial cells. The Rho GTPase family of proteins 
regulates VEGF secretion by cancer cells and regulates angiogenesis in vascular 
endothelial cells. Our study aims to elucidate the role of different isoforms of Rho 
GTPases in Astrocytoma cell expression of VEGF and blood vessels formation in 
vascular endothelial cells. The role of Rho GTPases in angiogenesis signaling was first 
examined in vascular endothelial cells. In ECV cells, the knock down of RhoA, RhoC 
and RhoG reduced the blood tubes formation. Knocking down StarD13, a RhoA and 
Cdc42 GAP, led to increase in angiogenesis and blood vessel formation. Second, the 
role of RhoA and RhoC on VEGF levels of expression on Astrocytoma cells was 
studied; results showed that RhoA regulated VEGF expression more efficiently than 
RhoC. The role of the PI3K pathway and VEGF secretion in SF268 Astrocytoma cells in 
response to EGF stimulation or in response to starvation was examined. The study 
showed that as the cancer cells are deprived from their physiological conditions for a 
longer period of time as they express more VEGF, MMP-2 and MMP-9. In addition, 
PI3K pathway is activated after EGF stimulation in tumor cells. In conclusion, this study 
will explicate the cross-talk between Astrocytoma cells and vascular endothelial cells 
and the pathways responsible for angiogenesis development 
 
Keywords: Angiogenesis, Rho-GTPases, PI3K, VEGF, MMP, Vascular Endothelial Cells, 
Astrocytoma 
viii 
 
Table of Contents 
 
Chapter             Page 
CHAPTER 1…………………………………………………………....…….……        1 
1. LITERATURE REVIEW:……………………………………………………..          1 
1.1. Cancer …………………………………………………………………….        1 
1.2. Angiogenesis ……………………………………………………………..         2 
1.3. The Phosphatidylinositol 3-kinase Pathway………………………………        6 
1.4. The Rho GTPases Family…………………………………………………      14 
CHAPTER 2……………………………………………………………………….       18 
2. MATERIALS AND METHODS:……………………………………………………        18 
2.1. Cells and Culture Conditions……………………………………………...      18 
2.2. Antibodies and Reagent ....………………………………………………..      18 
2.3. Cell Transfection and Small Interfering RNA ……………………………      18 
2.4. EGF Stimulation ……………………………………………...………......      19  
2.5. Western Blots ...……………………………………………...…………...       19 
2.6. Tube Formation Assay ...……………………………………………........       20 
2.7. Time Lapse Movies ………………………...……………...………….….       20 
2.8. Statistical Analysis………………………………………………………..       21 
CHAPTER 3……………………………………………………………………….       22 
3.RESULTS:.………………...……..…………………………...………………….        22 
3.1. The Effect of Rho GTPases on Tube Formation ……….…………...……       22 
3.2. Effect of RhoA on VEGF Levels of Expression ……………….……...…       39 
3.3. Effect of RhoA on MMP-2 Levels of Expression …………………..........       40 
3.4. Effect of RhoC on VEGF Levels of Expression …….................................      41 
3.5. Effect of ROCK2 on MMP-2 Levels of Expression ……………………...      42 
3.6. Effect of Starvation on VEGF, MMP-2 and MMP-9 Expression Levels…      43 
3.7. Effect of Starvation and Rho GTPase knockdown on VEGF Level of 
Expression……………………………………………………………………..       46 
3.8. Effect of EGF Stimulation on p-Akt Levels of Secretion…………………      47 
3.9. Effect of EGF Stimulation on VEGF Levels of Secretion………………..       48 
CHAPTER …………………………………………………………………...........       49 
4. DISCUSSION:....………………………………………………………………....        49 
CHAPTER 5……………………………………………………………………….       52 
ix 
 
5.CONCLUSION:………………….…………………………………………….              52 
BIBLIOGRAPHY………………………………………………………………..   53-62 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
List of Figures 
Figure 1 The Six Hallmarks of Cancer……………………………...………..........1 
Figure 2 The Angiogenic Flow……………………………………………...……..3 
Figure 3 Structure of VEGF RTKs ……………………………………...………...5 
Figure 4 The Three Different Classes of PI3K……………………………...……..8 
Figure 5 Class I PI3K Signaling Pathway……………………………………...…10 
Figure 6 The Regulatory Pathway of Rho GTPases …………………..…………15 
Figure 7 Plan Summarizing Different Pathways of the Study………………...….17 
Figure 8 Effect of RhoA on Angiogenesis ...………………….. ………………...23 
Figure 9 Effect of DLC2 on Angiogenesis ............................................................25 
Figure 10 Effect of Cdc42 on Angiogenesis………………………………….……27 
Figure 11 Effect of ROCK1 on Angiogenesis …………………….…………..…..29 
Figure 12 Effect of ROCK2 on Angiogenesis ……………….……….……….…..31 
Figure 13 Effect of RhoG on Angiogenesis ………………………………...……..34 
Figure 14 Effect of RhoC on Angiogenesis ……………………………...………..36 
Figure 15 Effect of Rac1 on Angiogenesis ……………………………….….....…38 
Figure 16 Effect of RhoA on VEGF Levels of Expression ……………………….39 
Figure 17 Effect of RhoA on MMP-2 Levels of Expression ……………………...40 
Figure 18 Effect of RhoC on VEGF Levels of Expression. ………………............41 
Figure 19 Effect of ROCK2 on MMP-2 Levels of Expression. …………………..42 
Figure 20 Level of Expression of VEGF after Different Times of Starvation ……43 
Figure 21 Level of Expression of MMP-2 after Different Times of Starvation …..44  
Figure 22 Level of Expression of MMP-9 after Different Times of Starvation …..45 
Figure 23 Level of Expression of VEGF after Different Times of Starvation and 
siRhoA Knockdown ………………………………….………………...46 
Figure 24 Level of Secretion of p-Akt after EGF Stimulation …………………....47  
Figure 25 Level of Secretion of VEGF after EGF Stimulation …………………...48 
 
 
 
xi 
 
List of Abbreviations  
PI3K: Phosphatidylinositol-3-Kinase 
Akt: Acutely Transforming Retrovirus 
GTPase: Guanosine Triphosphatase  
Rho: Ras Homologous Member  
Rac: Ras-Related C3 Botulinum Toxin Substrate  
Cdc42: Cell Division Cycle 42 
GDP: Guanosine Diphosphate  
GTP: Guanosine Triphosphate  
GEF: Guanine Nucleotide Exchange Factor 
GAP: GTPase Activating Protein 
GDI: Guanine Nucleotide Dissociation Factor 
EGF: Epidermal Growth Factor  
VEGF: Vascular Endothelial Growth Factor  
VEGFR: Vascular Endothelial Growth Factor Receptor  
RhoA: Ras Homologous Member A 
RhoC: Ras Homologous Member C 
RhoG: Ras Homologous Member G 
ROCK1: Rho-Associated Coiled Coil-Containing Protein Kinase1  
ROCK2: Rho-Associated Coiled Coil-Containing Protein Kinase2 
DMEM: Dulbecco`s Modified Eagle Medium 
RPMI-1640: Roswell Park Memorial Institute-1640  
FBS: Fetal Bovine Serum 
siRNA: Small Interfering Ribonucleic Acid  
SDS-PAGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis  
PVDF: Polyvinylidene Fluoride 
PBS: Phosphate Buffered Saline 
ECL: Enhanced Chemiluminescence  
BSA: Bovine Serum Albumin 
HEPES: 4-(2-hydroxyethyl)-1-piperazinethanesulfonice Acid  
DLC1: Deleted in Liver Cancer 1 
xii 
 
DLC2: Deleted in Liver Cancer 2 
MMP-2: Matrix Metalloproteinase-2  
MMP-9: Matrix Metalloproteinase-9 
ECV: Vascular Endothelial Cells  
SDS: Sodium Dodecyl Sulfate 
Rac1: Ras-Related C3 Botulinum Toxin Substrate 1 
CNS: Central Nervous System  
WHO: World Health Organization  
GBM: Glioblastoma Multiforme  
EC: Endothelial Cells  
ECM: Extra Cellular Matrix  
RTK: Receptor Tyrosine Kinase  
Bcl-2: B-Cell Lymphoma-2 
VPF: Vascular Permeability Factor  
kDa: Kilo Dalton  
VEGF-A: Vascular Endothelial Growth Factor-A  
MAPK: Mitogen Activated Protein Kinase 
MT-MMP: Membrane Type-Matrix Metalloproteinases  
BM: Basement Membrane 
PI-3,4,5-Pз: Phosphatidylinositol-3,4,5-triphosphate  
PPI: Phosphorylated Ptdlns Derivatives 
Ptdlns: Phosphatidyl-inositol  
GPCR: G-Protein Coupled Receptor  
RasBD: Ras Binding Domain  
PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha  
PIK3CB: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta 
PIK3CD: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta  
p85BD: p85 Binding Domain 
PIK3R1: Phosphoinositide-3-kinase regulatory subunit 1(alpha)  
PIK3R2: Phosphoinositide-3-kinase regulatory subunit 2(beta)  
PIK3R3: Phosphoinositide-3-kinase regulatory subunit 3(gamma)  
xiii 
 
SH2: Src-Homology 2 
SH3: Src-Homology 3 
BH: Breakpoint Cluster Region Homology  
PI-3-P: Phosphatidylinositol 3-phosphate  
PI-3,4-P₂: Phosphatidylinositol 3,4- bisphosphate  
PI: Phosphatidylinositol 
PI3KC2α: Phosphatidylinositol 3-kinase class II α  
PI3KC2β: Phosphatidylinositol 3-kinase class II β 
PI3KC2γ: Phosphatidylinositol 3-kinase class II γ 
Vsp34: Vascular Protein Sorting 34 
mTOR: Mammalian Target of Rapamycin  
inter-SH2: inter-Src Homology 2  
PKB: Protein Kinases B 
PH: Pleckstrin Homology  
PDK1: Phosphoinositide Dependent Protein Kinase 1 
mTORC2: Mammalian Target of Rapamycin Complex 2  
BAD: Bcl-2 Associated Death promoter protein  
BAX: Bcl-2 Associated X Protein  
FOX: Forkhead Box 
MDM2: Mouse Double Minute 2 Homolog  
Rheb: Ras Homolog Enriched in Brain 
TSC2: Tuberous Sclerosis 2 
GTP: Guanosine-5-triphosphate  
mTORC1: Mammalian Target of Rapamycin Complex 1 
IRS1: Insulin Receptor Substrate 1 
PTEN: Phosphatase and Tensin Homolog Deleted on Chromosome TEN 
RBD: Ras Binding Domain  
Tie: Tyrosine Kinase With Immunoglobulin and EGF Homology Domains  
Tyr1213: Tyrosine 1213 
Tyr1333: Tyrosine 1333 
Akt-DN: Acutely Transforming Retrovirus-Dominant Negative 
xiv 
 
RCAS: Replication Competent ALV LTR with a Splice Acceptor 
FOXO: Forkhead Box Protein O1 
NOS: Nitric Oxide Signaling 
HIF-1α: Hypoxia Inducible Factor-1Alpha  
ERK1/2: Extracellular Signal Regulated Kinase 1 and 2 
NF-ⱪB: Nuclear Factor Kappa Light Chain Enhancer of Activated B Cells 
Cdc42: Cell Division Cycle 42 
Arp2/3: Actin Related Proteins 2/3 
PIP2: Phosphatidyl 4,5-bisphosphate 
PIP3: Phosphatidylinositol (3,4,5)-triphosphate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Chapter One 
 
Literature Review  
 1.1. Cancer 
 
           1.1.1. Background 
      Cancer is a multi-factorial complex disease and the leading cause of mortality 
worldwide. Most types of cancers begin with the abnormal proliferation of cells 
(American Cancer Society, 2014). Nonlethal genetic damage leading to cancer can 
be inherited, acquired or both. Mutations in oncogenes and tumor suppressor genes 
lead to the development of cancer cells. These cancer cells have different 
characteristics referred to as the “Hallmarks of Cancer” (Figure 1). These hallmarks 
include the ability of cancer cells to sustain proliferative signaling, evade suppressors 
of growth, resist cell death, induce the formation of angiogenesis, replicate in an 
uncontrollable manner and acquire the ability to metastasize and invade (Hanahan & 
Weinberg, 2011).   
 
 
Figure 1: The Six Hallmarks of Cancer. This figure shows the six different hallmarks of cancer. (Source: 
Hanahan & Weinberg, 2011) 
 Cancers can be classified depending on the origin of the tissue where they 
originate. Five categories have been identified: carcinoma is cancer of the epithelial 
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tissues, sarcoma is cancer of the connective tissues, leukemia is cancer that starts in 
the hematopoietic system, CNS cancers are cancers that occur in the brain or the 
spinal cord and the last category is the lymphoma and myeloma, which are cancer 
cells that originate in the lymphoid system (National Cancer Institute, 2014).  
 
               1.1.2. Brain tumors  
         Brain tumor is the growth or formation of atypical cells in the tissues of the 
brain. In 2014, there were 14,320 cases of death from brain tumors in United States 
(National Cancer Institute, 2014). Several factors can lead to the formation of brain 
tumors including genetic and environmental factors such as natural or chemical 
carcinogens (Wrensch et al., 2002).  
 The World Health Organization (WHO) recognized four grades of malignant 
brain tumors. Starting with Grade I tumors, which are known to be the least 
aggressive tumors and Grade IV, which are known to be the most aggressive tumors 
(Collins, 2004). Grade I tumors are characterized by being slow growing. Grade II 
tumors grow slowly however they invade nearby healthy tissues, this grade manifests 
atypia. Grade III brain tumors are known as Anaplastic Astrocytoma. These grow 
rapidly and have the ability to invade neighboring healthy cells. Grade IV brain 
tumors are called glioblastoma, they are very aggressive and malignant (Biernat, 
Tohma, Yonekawa, Klehihues & Ohgaki, 1997).  
Treatment of glioblastoma includes surgery which is followed by 
chemotherapy in addition to radiotherapy. Glioblastoma (GBM) is characterized by 
focal necrosis and neovascularization which is the ability to form excessive blood 
vessels forming tumor angiogenic regions (Goldman et al., 1992).   
 
 1.2. Angiogenesis  
 
    1.2.1. Role of angiogenesis in cancer  
Angiogenesis is a physiological process needed for embryogenesis and 
wound healing. It is also important under pathological conditions, particularly tumor 
formation. Angiogenesis, one of the six known hallmarks of cancer, is due to 
endothelial cells` extreme propagation and transformation (Nikitenko & Boshoff, 
2006). Angiogenesis is the ability of new blood vessels to form due to change in 
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morphology of endothelial cells and stem cells. During tumor growth, angiogenesis 
starts when endothelial cells branch from existing small vessels forming sprouts of 
capillaries that can supply the tumor with oxygen and nutrients and potentially 
provide venues for metastasis (Zhao et al., 2006). Angiogenesis depends on the 
increase in endothelial cells permeability. As the new endothelial cells form new 
blood vessels, they also need metalloproteases (MMPs) in order to degrade the 
basement membrane (Figure 2) (Bryan & D`amore, 2007).   
Tumor metastasis is also dependent on angiogenesis which is activated by 
signals from cells of tumor that undergoes rapid growth (Folkman, 1971). 
 
Figure 2: The Angiogenic Flow. Angiogenesis which is blood vessel formation occurs when the steady vessels 
(a) demonstrate an increase in the vascular permeability which leads to extravasations of proteins (b).  MMPs 
lead to ECM deprivation which relieves the pericyte-EC contacts and liberates extracellular matrix sequestered 
growth factors (c). Endothelial cells then will move around to a final target (d) and gather to undergo 
morphogenesis (e). (Source: Bryan & D`amore, 2007).   
 
Hence one of the major factors for cancer progression is angiogenesis. The formation 
of new blood vessels during tumor angiogenesis involves four basic and essential 
steps. The first step is the local injury of the basement membrane which leads to 
hypoxia. The second step is the migration of endothelial cells (EC) which are 
activated by angiogenic stimuli. The third step is the proliferation of the endothelial 
cells.  
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    1.2.2. Angiogenesis Signaling  
   
       1.2.2.1. Vascular Endothelial Growth Factor (VEGF) 
           VEGF or VPF is one of the most important growth factors for blood vessel 
formation and angiogenesis (Liang et al., 2001). The function of endothelial cells is 
regulated by VEGF. The VEGF family is formed from seven members that have the 
same common homology domain (Hoeben et al., 2004). These seven different VEGF 
members are: VEGF-A, VEGF-B VEGF-C, VEGF-D, VEGF-E, VEGF-F and PIGF 
(Hoeben et al., 2004). Many cells produce VEGF and the most common cells that 
lead to VEGF production are endothelial cells. VEGF is also secreted by cancer cells 
due to hypoxia as the tumor grows for blood recruitment (Shweiki et al., 1992). 
VEGF is active and performs its activity only when it is bound to the VEGF 
receptors, which are stimulated by lymphatic and vascular endothelial cells 
(Lamalice et al., 2007). VEGF-A has an important function in angiogenesis and tube 
vessels formation. Mice that have a knockout in VEGF-A gene die in their embryonic 
developmental stage due to vasculature defects (Ferrara et al., 1996). VEGF-A has 
five isoforms; VEGF121, VEGF145, VEGF165, VEGF189 and VEGF206 (Olsson, 
Dimberg, Kreuger & Claesson-Welsh, 2006). Binding of VEGF to VEGF-R results 
in the activation of several downstream signaling pathways such as the PI3K and 
MAPK cascades that eventually manage the angiogenesis process (Bryan & 
D`amore, 2007). VEGF-R is made up of three members: VEGFR1, VEGFR2 and 
VEGFR3, all of which play important roles in angiogenesis. VEGFR1 is essential for 
angiogenesis development, its role vary in the stage of development and physiologic 
conditions. VEGFR2 mediate the downstream effects of VEGF such as migration, 
invasion and survival. VEGFR3 is essential for lymph node metastasis and was 
observed in solid types of tumor. In addition to its function in blood vessels 
formation, VEGF is essential in the reproductive system of females in addition to the 
formation of bones (Ferrara, 2001).  The expression of Bcl-2 and A1 proteins in 
endothelial cells (EC) is also induced by VEGF (Gerber, Dixit, & Ferrara, 1998).  
VEGF receptors are known to be localized on the surface of ECs however they may 
be also expressed by cancer cells.  
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The two receptor tyrosine kinases that mediate the VEGF activity are 
VEGFR-1 and VEGFR-2 (Ferrara et al., 2003). These are single trans-membrane 
receptors (Figure 3) that are necessary components for migration, proliferation and 
segregation. The VEGF receptors are activated through the binding of a ligand 
leading to dimerization and automatic phosphorylation of the cytoplasmic parts of 
the receptors at tyrosine residues. The phosphorylated tyrosine residues establish 
binding sites for downstream proteins (McMahon, 2000).  
 
Figure 3: Structure of VEGF RTKs. The VEGFR are known by seven loops. These seven loops can bind to 
VEGF. Only two VEGF receptors can undergo dimerization in addition to automatic phosphorylation on the 
cytoplasmic portion. (Source: McMahon, 2000).  
 
    1.2.2.2. MMPs  
 Matrix metalloproteinases are also known as matrixins. MMPs are over 20 
endopeptidases that belong to the metzinc family; the main function of these MMPs 
is to dissolve or degrade the different components of the extracellular matrix (ECM) 
(Nagase & Woessner, 1999). These are divided into different groups depending on 
their structural differences (McCawley & Matrisian, 2001). The simplest structural 
form of MMPs is called matrilysins. This form is made up of one peptide, pro-
peptide and a catalytic domain that contains a binding site for zinc (Lynch & 
Matrisian, 2002). The stromelysins play a function in the degradation of many 
extracellular matrix proteins. Gelatinases contain an extra region of three fibronectin 
type II and have a high ability to degrade gelatin (Lee & Murphy, 2004). Membrane 
type matrix metalloproteinases are attached to the surface of a cell through a C 
terminus trans-membrane domain (Lynch & Matrisian, 2002).   
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 MMP-2 which is also known as collagenase type IV can lead to the cleavage 
of different types of collagen such as type IV and V in addition to type I gelatin (Lee 
& Murphy, 2004). For the secretion of MMP-2 to be activated, the Ras pathway 
should also be activated (Lynch & Matrisian, 2002).  MMP-9, a 92kDa protein, 
degrades the collagen of bones with the help of MMP-1 and cysteine proteases. 
MMP-9 can also play a role in the oesteoclastic resorption of bones (Nagase & 
Woessner, 1999).  
 
     1.2.2.3. Role of MMPs in angiogenesis  
 MMPs play an important and crucial role in angiogenesis. MMP-9 enhances 
the growth of endothelial cells (Pozzi, LeVine, & Gardner, 2002). Matrix 
metalloproteinases break the adhesion between two cells via the cleavage of ecto-
domain of the VE-cadherin (Herren et al., 1998). Both MMP-2 and MMP-9 are 
critical for the angiogenesis switch the moment the tumors become highly 
vascularized.  However in some cases the angiogenesis process can be MMP 
independent. 
Angiogenesis needs the degradation of the extra cellular matrix barrier of the 
blood vessel by matrix metalloproteinase (Sang, 1998). Collagen is one of the key 
proteins which are linked to angiogenesis especially in vivo (Ray & Stetler, 1994). 
The matrix is broken down as a result of collagen loss. This identifies the enzyme 
“collagenase” as an important key enzyme for blood vessels and sprouts formation 
(Ray & Stetler, 1994).  
In conclusion, tube formation requires that the basement membrane gets 
dissolved by proteinases. MMP-2 and MMP-9 act on the fragmentation of type IV 
collagen of the basement membrane (Moses, 1997).  
 
1.3. The Phosphatidylinositol 3-Kinase Pathway 
 
 1.3.1. The PI3K pathway components  
     1.3.1.1. PI3K 
 PI3Ks which are phosphoinositide-3 kinases belong to the family of lipid 
kinases that phosphorylate the inositol ring 3’OH group present in the inositol 
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phospholipids to produce PI-3,4,5-Pз (Frenso Vara et al., 2004). Phosphoinositide-3 
kinases generate phosphorylated Ptdlns derivatives (PPI) through phosphate group 
addition to inositol-glycero-phospholipids (Liu et al., 2009). PI3Ks are implicated in 
cell growth regulation, motility, migration, metabolism and glucose regulation, in 
addition to vesicle trafficking (Engelman et al., 2006). The majority of PI3Ks are 
attached to the regulatory subunit. This attachment leads to the determination of the 
signals that regulate the activity of the subunit itself (Cantley, 2002). The PI3K 
family contains three different classes or members (class I, class II, and class III) that 
are divided on the basis of their specificity to the substrate and the characteristics of 
the structure (Figure 4) (Liu et al., 2009).   
Class I kinases are further subdivided into class IA and class IB. Class IA is 
activated through receptor tyrosine kinases (RTKs), G protein coupled receptors and 
specific oncogenes (Liu et al., 2009). Class IA is known to be heterodimer with both 
a regulatory and a catalytic subunit (Figure 4). The regulatory subunit is referred to 
as p85 and the catalytic subunit is known as p110 (Engelman et al., 2006). Binding 
of the receptor, activation of the enzyme in addition to the enzyme localization all are 
mediated by p85 (Liu et al., 2009). RTKs are activated in response to stimulation 
with growth factors; this recruits PI3K to the membrane through the interaction of 
the regulatory subunit to adaptor proteins related to the receptor or even to the 
receptor itself (Engelman et al., 2006). The catalytic subunit activates many 
downstream pathways through the generation of PI-3,4,5Pз. Three genes are present 
in mammals for this class; the PIK3CA, the PIK3CB and the PIK3CD (Engelman et 
al., 2006).  The expression of p110α and p110β is ubiquitous however p110γ 
expression is only limited to the immune system (Katso et al., 2001). These genes 
encode the p110 isoforms, p110α, p110β and p110γ respectively (Figure 4).  These 
isoforms are homologous and share five different domains (Figure 4): p85BD that 
binds to the p85 subunit, RasBD, helical domain, C2 membrane binding domain and 
C-terminal kinase (Liu et al., 2009). P85α, p85β and p55γ are encoded by PIK3R1, 
PIK3R2 and PIK3R3 respectively (Figure 4). These isoforms contain an inter-SH2 
core domain which is present between two SH2 domains. SH3 and BH domains are 
present in both p85α and p85β (Liu et al., 2009). Class IBs also consist of a 
heterodimer that is formed from both a regulatory subunit and a catalytic subunit 
(Figure 4). The regulatory subunit is known as p101 and the catalytic subunit is 
known as p110γ (Katso et al., 2001). Recently, p84 and p87PIKAP are new 
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regulatory subunits that are being described (Voigt, Dorner & Schaefer, 2006). The 
catalytic subunit activation occurs by GPCRs via p101 interacting with trimeric G 
proteins at the Gβγ subunit (Katso et al., 2001).  
 
Class II PI3K lacks a regulatory subunit and it has only a catalytic one which 
use PI-3-P to produce PI-3,4-P₂, in addition this class can lead to the production of 
PI-3-P from PI (Carracedo & Pandolfi, 2008). In this class three isoforms are present 
which are the PI3KC2α, the PI3KC2β and the PI3KC2γ (Liu et al., 2009). These 
isoforms can be in the active state in reaction to RTKs and integrin receptors 
(Engelman et al., 2006). This class of PI3K also might be involved in the actin 
cytoskeleton reformation, in addition to cell metastasis and migration in cells which 
are non-immune (Domin et al., 2005).  
 
 
 
Figure 4: The Three Different Classes of PI3K. Phosphoinositide 3-kinase includes three members that are 
divided based on the specificity of the substrate in addition to the structural properties. Class I is subdivided into 
class IA and class IB. Class IA is made up of both a p110 catalytic and p85 regulatory subunit.  Class IB is a 
heterodimer made up of p110γ catalytic subunit in addition to a p101 regulatory subunit. Class II only contains a 
catalytic subunit without or lacking a regulatory one. Class III consists of only a catalytic subunit known as 
Vps34 (Source: Liu et al., 2006).  
 Class III PI3K, is also abbreviated by Vps34 which stands for vascular 
protein sorting 34. This class was first discovered in Saccharomyces cerevisiae 
(Herman & Emr, 1990). The Vps34 is responsible for vesicle trafficking in addition 
to enhancing the regulation of mTOR pathway through cross talking with both 
subdivisions of class I (Backer, 2008).  
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     1.3.1.2. Akt/Protein kinases B (PKB)  
         Upon the activation and 3`phosphorylation of PI-4,5-P₂ via PI3K, proteins 
which harbor a PH or a PH-like domain are recruited to the interior of the plasma 
membrane where they convey signals related to this activation (Engelman et al., 
2006). One of these proteins is a serine/threonine kinase known as akt kinase or 
protein kinase B (Liu et al., 2009). Akt kinases have three different isoforms (Akt1, 
Akt2 and Akt3) that are determined by PKBα, PKBβ and PKBγ (Liu et al., 2009). 
The three isoforms share a common structure made up of N- terminal domain that 
has a PH domain, a catalytic domain which is a serine/threonine, and C terminal area 
that has a regulatory domain (Scheid & Woodgett, 2003). Akt binds to PIP3 once it is 
formed via the PH domain; nevertheless it stays inactive. PDK1 and mTORC2 which 
are phosphoinositide binding proteins are required for the activation (Sarbassov, 
Guertin, Ali & Sabatini, 2005). Akt is recruited to plasma membrane upon the 
binding of PDK1 to PIP3, this allows a change in the conformation leading to Akt 
phosphorylation at Thr308. Akt is also phosphorylated at Ser473 which is embedded 
by mTORC2, permitting the overall activation of the protein (Sarbassov, Guertin, Ali 
& Sabatini, 2005). The active Akt can then regulate cell growth, cell proliferation as 
well as angiogenesis (Manning & Cantley, 2007). Inhibition of proteins that are 
involved in apoptosis, for example inhibition of the pro-apoptotic proteins Bax and 
BAD that are found in the Bcl2 family allow the cell survival via Akt (Engelman et 
al., 2006). In addition Akt inhibits p53 which is a tumor suppressor through MDM2 
phosphorylation (Duronio, 2008).  
 
10 
 
 
Figure 5: Class I PI3K Signaling Pathway. This is a pathway diagram showing the effect of PI3K signaling pathway 
on cell growth, metabolism, proliferation and angiogenesis. Arrows shows activation however bars represent 
inactivation or inhibition. (Source: Courtney et al., 2010).  
 
            1.3.2. PI3K signaling pathway in cancer  
The PI3K/Akt pathway was shown to be associated with many types of 
cancers (Frenso Vara et al., 2004). In different types of tumors, class I PI3K was 
mainly mutated and non-functional (Samuels et al., 2004).  Evidence shows that 
tumorgenesis is linked to PI3K class I. Class II and III are not involved in 
tumorgenesis due to the lack in the production of PIP3 which is a key regulator in 
cell growth and proliferation (Zhao and Vogt, 2008). PIK3CA is the gene coding for 
the catalytic subunit in PI3K class I which is the p110α; hence any active mutation 
taking place in this gene can lead to the various types of tumor (Samuels et al., 
2004). Indeed two hot spots for mutations are located at the helical domain level in 
exon 9 and a third found in the kinase domain level in exon 20 which blocks the 
inhibitory interaction between the SH2 domain of p85 (regulatory subunit) and 
p110α (catalytic subunit) (Wong, Engelman & Cantley, 2010).All these previous 
mutations lead to an increase in activity of the catalytic domain thus promoting high 
production of PIP3. High levels of PIP3 will activate the Akt pathway, leading to cell 
transformation both in vitro and in vivo (Samuels et al., 2004).  Studies showed that 
around 30% of cancer shows these types of mutations (Ikenoue et al., 2005).  
PIK3R1 which is a gene that codes for the p85 regulatory subunit is a target for PI3K 
mutations. This class of gene mutation occurs in glioblastomas, colorectal and 
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ovarian types of cancer (Mizoguchi, Nutt, Mohapatra & Louis, 2004). The result of 
this mutation is deletions in the inter-SH2 domain that is found in the p85 subunit 
which interacts with p110 removing the inhibition activity of p85 (Huang et al., 
2007).  
Overexpression of PDK1 in breast cancer (20%) was observed despite the 
fact that mutation in PDK1 is rare (Hunter et al., 2006). The overexpression of Akt1 
and 2 in several other different cancer types was also found (Liu et al., 2009).  
Ovarian, breast and melanoma cancers exert mutation in Akt1 specifically at the lipid 
PH domain (Carpten et al., 2007). Colorectal cancer expresses mutations in Akt2 
specifically in the kinase area (Parsons, Daley, Begh & Aveyard, 2005).   
PTEN is a gene identified as a tumor suppressor by negatively regulating 
AKT signaling pathway. It contains both a tensin and a catalytic domain. It 
dephosphorylate the phosphoinositide substrates (Salmena, Carracedo & Pandolfi, 
2008). Mutations in PTEN gene occurs on chromosome number 10; in which they 
are lost in several types of cancer (Steck et al., 1997). The expression of PTEN is 
under the control of transcriptional and post translational stages (Salmena, Carracedo 
& Pandolfi, 2008). Genetic as well as epigenetic factors can lead to the loss of 
PTEN. Genetic mutations can occur in catalytic domain or in uniquitinylation 
subunits. Once this type of mutation takes place, the PTEN will lose the ability of 
functioning hence cancer will develops and migrates (Trotman et al., 2007). 
Repression of transcription in addition to epigenetic mutations (silencing) can also 
lead to PTEN loss of function (Garcia et al., 2004). PTEN malfunctioning will lead 
to loss of activity of its lipid phosphatase. This loss of activity can accumulate PIP3 
and activates both the PI3K and Akt pathways resulting in growth of cell and 
survival (Haas-Kogan et al., 1998). Melanoma, kidney, colon, prostate and 
glioblastoma cancer all showed PTEN gene inactivation (Hollander, Blumenthal & 
Dennis, 2011). PTEN which is a tumor suppressor is the key that associate human 
cancer and PI3K signaling pathway mutually.   
 
 1.3.3. PI3K signaling pathway in angiogenesis 
 Angiogenesis is triggered by growth factors which are cellular signals, 
activation of PI3K oncogenes which are genetic alternations, and by mutations of 
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PTEN and p53 (Carmeliet & Jain, 2000). Studies showed that VEGF has a critical 
function in the growth of tumor as well as angiogenesis.  
 VEGFR1 interacts with the regulatory subunit (p85) of PI3K specifically at 
the two sites Tyr1213 and Tyr1333 which cross talk with VEGF receptor 2 to control 
migration of cell and angiogenesis (Autiero et al., 2003). Angiogenesis signaling 
includes the predominant VEGFR2 as a regulator for permeability of vessels, EC 
migration and survival (Cebe-Suarez, Zehnder-Fjallman & Ballmer-Hofer, 2006). 
Studies showed that Tyr799 and Tyr1173 of VEGF receptor 2 are binding targets of 
the regulatory subunit and also that PI3K activation is important for EC proliferation 
(Dayanir, Meyer, Lashkari & Rahimi, 2001). Previous work showed that 
phosphorylation of the regulatory subunit p85 that caused increase in the activity of 
PI3K and Akt is due to the association of VEGFR2 with p85 of PI3K (Gerber et al., 
1998). Endothelial cell survival induced by VEGF was inhibited upon treatment with 
Wortmanin which is a PI3K inhibitor (Gerber et al., 1998). Hence regulation of 
angiogenesis was shown to be mediated by the PI3K/Akt pathway. This mediation in 
vivo was first observed by inducing the expression of PI3K/Akt via the vector system 
“RCAS” (Jiang & Liu, 2008). PI3K or/and Akt over expression led to angiogenesis 
however PTEN over expression blocked angiogenesis in embryos of chicken. This 
suggests that the PI3K pathway is needed for embryonic vasculature and 
angiogenesis (Jiang & Liu, 2008). Vascular malfunctioning and defects such as head 
vessel dilation and reducing branching are all shown in deficient mice in the catalytic 
subunit p110α of PI3K (Lelievre, Bourbon, Duan, Nussbaum & Fong, 2005). 
Vascular permeability was blocked in mice that were deficient with p110γ; this 
highlights the important key factor that PI3Kγ plays in vessel permeability (Serban, 
Leng & Cheresh, 2008). Akt was established as homolog of viral oncogene 
(Bellacosa, Testa, Staal & Tsichlis, 1991).       ʹ  mice showed a high level of fetal 
death as a result of impaired vascularization and hypotrophy in placenta, which 
signifies the important function that Akt1 plays in the development of fetus and 
vasculature (Yang et al., 2003). AKT1 is one of the major isoforms in vascular 
endothelial cells.       ʹ  mice have shown non functional vessel formation and 
sprouting because of decrease in the eNOS activation (Chen et al., 2005).  
Receptor Tyrosine Kinase can lead to the activation of PI3K upon VEGF 
stimulation which can apply an effect via AKT as well as other targets in endothelial 
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cells (Liu et al., 2009).  Down streams targets can allow PI3K and AKT to regulate 
angiogenesis. Some of the examples of these targets are FOXO inhibition, NOS 
induction, mTOR signaling and GSK-3β inhibition (Engelman et al., 2006). These 
stated targets can increase the expression of HIF-1α which leads to VEGF induction 
in endothelial cells (Kaidi, Williams & Paraskeva, 2007). Production of HIF-1α is 
induced by hypoxia via the ERK1/2 pathway activation. PI3K is stimulated by 
hypoxia which leads to expression of VEGF in a dependent manner with HIF-1 as 
well as through PI3K/ROCK/Rho pathway (Mizukami et al., 2006). VEGF 
expression can be induced by PI3K via ERK1/2, HIF-1 and NF-ⱪB regulation in 
order to form angiogenesis (Engelman et al., 2006). Evidence has proven the major 
roles that AKT, mTOR, PI3K and the growth factor “VEGF” in addition to HIF-1 
has in cancer angiogenesis (Xia, Meng, Cao, Shi & Jiang, 2006). VEGF expression 
can be increases in response to PI3K activation in endothelial as well as in cancer 
cells (Jiang & Liu, 2009). The microenvironment of the tumor which is made up of 
cancer cells and vascular cells regulates angiogenesis. The microenvironment which 
consists of EC is controlled by the PI3K pathway (Yuan & Cantley, 2008). Migration 
and proliferation of endothelial cells is regulated by PI3K via NOS and FOXO which 
are downstream targets that lead to tumor vascularization and angiogenesis 
regulation (Jiang & Liu, 2009). During tumorgenesis and development, PI3K 
specifically class IA plays a role in regulation of vessel integrity (Yuan & Cantley, 
2008). Studies have showed that p110α which is an isoform of p110 is needed for the 
control of EC angiogenesis. Endothelial cells (EC) with p110α  ʹ  can cause 
embryonic mortality with malfunctioning in the sprout remodeling (Jiang & Liu, 
2009). Endothelial cells with PTE   ʹ  can lead to embryonic mortality as a result of 
defected vascular remodeling. Endothelial cells with PTEN +/- enhance angiogenesis 
in which growth of tumor will increase (Suzuki, Hamada, Sasaki, Mak & Nakano, 
2007). Growth factors in cancer cells can activate PI3K/Akt pathway leading to 
VEGF production resulting in switching angiogenesis, activating endothelial cells 
and increasing permeability by PI3K (Jiang & Liu, 2009). In conclusion, both the 
PTEN and PI3K pathways play a key role in regulating angiogenesis via the 
association of tumor cells specifically endothelial cells and microenvironment. 
Angiogenesis is induced via growth factors; the most important one is VEGF which 
activates the PI3K signaling pathway. Any genetic defects in the PI3K can result in 
the dysfunction of angiogenesis and sprouting (Jiang & Liu, 2009).  
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Due to the key role that PI3K plays in angiogenesis regulation, PI3K and Akt 
inhibitors were used as treatment for cancer. Wortmannin which is a PI3K inhibitor 
works on inhibiting proliferation of cancerous cells in addition limits their growth 
(Granville, Memmott, Gills & Dennis, 2006). Wortmannin which was isolated in 
1957 from a fungus called Penicillium wortmanni interacts with PI3Kα catalytic 
domain specifically at Lys802 in addition to PI3Kγ at Lys833 to exert its inhibitory 
effect (Jiang & Liu, 2009). Wortmannin is known to be toxic; it works on directly 
targeting enzymes related to PI3K which reduce the clinical usage of these inhibitors 
(Marone, Cmiljanovic, Giese & Wymann, 2008).  
 
1.4. The Rho GTPases Family  
       1.4.1. The Rho GTPases family and their function in cancer 
 The Rho GTPase family is involved in the regulation of biological and 
cellular activities such as actin cytoskeleton, cell migration and proliferation (Zhao et 
al., 2006). Rho GTPases belongs to the Ras family members which share a homology 
domain. Rho GTPases were discovered in 1981 and found to be conserved in plants, 
mammals and yeast (Freyer & Field, 2005). Twenty homologues of Rho which range 
between 20-40KDa were discovered (Burridge & Wennerberg, 2004). The major 
ones are RhoA, RhoC, RhoG, Cdc42 and Rac1 (Burridge & Wennerberg, 2004). Rho 
GTPases act as switches between active GTP-binding state and inactive GDP-
binding state (Boettner & Van Aelst, 2002). They get activated by a GEF (guanine 
nucleotide exchange factor) which is a PI3K dependent kinase that leads to GTP 
exchange (Schmidt & Hall, 2002). GTPases activating proteins lead to the 
inactivation of Rho GTPases (Schmidt & Hall, 2002) (Figure 6). Rho GTPase 
proteins are key players in several biological and cellular functions such as apoptosis, 
cell cycle and gene transcription. However their major role is to regulate the actin 
cytoskeleton during cell migration and cancer cell metastasis (Laufenburger & 
Horwitz, 1996). Cellular motility starts by the determination of direction of 
movements which is done by Cdc42. Cdc42 also has the ability to sense the direction 
of movement in chemotaxis, regulation of the actin cytoskeleton and cell polarity 
maintenance (El Sibai et al., 2007). Cdc42 leads to the induction of Rac dependent 
formation of lamellipodia (Hall, 1998). Rac also has another function which is the 
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activation of the Arp2/3 which enables lamellipodia formation (Condeelis et al., 
2001), (Nobes & Hall, 1995). Upon the lamellipod formation and extension, Rac 
then works on focal complexes which help in stabilizing the lamellipodia through the 
interaction with the ECM (Rottner, Hall & Small, 1999). Contractility which is a 
major factor for migration and motility is not ensured by focal complex unless they 
mature and become focal adhesions via the action of RhoA (Kaverina, Krylyshkina, 
& Small, 2002). Focal adhesions have specific characteristics in which they are large 
in size, gives mechanical stability and strength to the cells which will end in giving 
final motility to the cells after contraction (Gupton & Waterman-Storer, 2006).  
 
Figure 6: The Regulatory Pathway of Rho GTPases. Rho proteins has the ability to function as molecular 
switches. Rho GTPases activity is regulated by the nucleotide binding status which is under the regulation of 
three proteins: GEF, GAP and GDI. (Source: Aktories & Barbieri, 2005).  
 
 1.4.2. The role of Rho GTPases in endothelial cells and angiogenesis  
Many reports state that Rho GTPases have an important function in 
transmitting downstream signals of vascular endothelial growth factor (Bryan & 
D`amore, 2007). Rho GTPases mediate angiogenesis in endothelial cells in response 
to the VEGF signaling pathway. Some of the Rho proteins such as Rho, Rac and 
Cdc42 regulate the stress fiber as well as the cell-cell interaction in response to 
VEGF signaling. In addition, Rho and Rac regulate permeability of thrombin and 
ECV polarization (Freyer & Field, 2005). Rho GTPases plays a major function and 
role in endothelial cells in all the steps needed for angiogenesis (Van Der Meel et al., 
2011).  The first step needed for angiogenesis is vascular permeability. Actin 
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cytoskeleton regulation is mediated by Rho GTPases which lead to interference with 
the cell-cell junctions. Tumor cells secrete the growth factor VEGF which leads to 
the activation of Rho GTPases in endothelial cells resulting in junction disruption 
(Van Der Meel et al., 2011). Increase in permeability of vessels was due to 
pulmonary endothelial cells as a result of vascular endothelial growth factor 
treatment. Vascular permeability has decreased upon Rac1 knockdown (Monaghan 
Banson & Burridge, 2009). Studies showed that RhoA mediates vascular 
permeability (Mehta & Malik, 2006). The second step needed for angiogenesis is the 
basement membrane degradation. Migration and invasion of the extra cellular matrix 
by endothelial cells is due to the degradation of the basement membrane by MMPs. 
A study has showed that RhoA has an opposite role with Cdc42 in the regulation of 
MMP-2; in which MMP-2 is activated by increase in the activity of Cdc42 and 
decrease in the activity of RhoA (Van Der Meel et al., 2011). Another study has 
confirmed that RhoA induce MMPs secretion which lead to extra cellular matrix 
remodulation (Turchi et al., 2003).  The third step needed for angiogenesis is 
migration. Filopodia formation is controlled via Cdc42 which is necessary for cell to 
cell interaction and environment sensing. Lamellipodia protrusion in the front of 
each cell is due to Rac1 however stress fibers formation at cell body is due to RhoA. 
Forward movement in addition to cell contraction is mediated by stress fibers 
(Heasman & Ridley, 2008). The fourth step needed for angiogenesis is proliferation. 
The Branches of vessels are formed with the help of cellular propagation and 
proliferation. In the cell cycle sequence specifically in G1/S phase, Rho GTPases 
were found to have a major role (Van Der Meel et al., 2011). Proliferation of cells 
has decreased by 80% upon inhibition of RhoA and RhoC (Van Der Meel et al., 
2011). The final step needed for angiogenesis is the formation of lumen. The 
angiogenesis process is made up of many steps however the final step is the lumen 
formation. Neovascularization was increased in response to ROCK inhibition (Van 
Der Meel et al., 2011).  
    Purpose of Study: 
In this research study, we wanted to establish the roles of the Rho GTPase 
family of proteins particularly RhoA, RhoC as well as RhoG in SF-268 
(Astrocytoma) cell secretion and expression of vascular endothelial growth factor 
(VEGF) and metalloproteinases and the resulting angiogenesis in ECV (Vascular 
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Endothelial Cells). The study is divided into studying different parts of the pathway 
(Figure 7). The first part of the pathway was studying the effect of the different Rho 
GTPases family of proteins on blood vessel formation in vascular endothelial cells 
using tube formation assay. The second part of the pathway was studying the effect 
of PI3K and different Rho GTPases effect on the levels of secretion and expression 
of VEGF and metalloproteinases specifically MMP-2 and MMP-9 in Astrocytoma 
cancer cells in response to starvation and EGF stimulation at short time intervals. In 
conclusion, this study will clarify the cross-talk between Astrocytoma cells and 
vascular endothelial cells and the different parts responsible for VEGF and MMPs 
levels of expression and secretion in addition to tube formation.   
 
 
Figure 7: Plan Summarizing Different Pathways of the Study. Diagram dissecting and highlighting the three 
different pathways of our study. First the plan is studying the effect of PI3K and Rho GTPases on the secretion of 
VEGF and metalloproteinases in Astrocytoma cells in response to starvation.  Second the effect of RhoGTPases 
on blood vessel tubes formation in vascular endothelial cells. (Source: El Sibai Laboratory, 2013) 
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Chapter Two 
 
Materials and Methods 
 
2.1. Cells and culture conditions 
       The cells cultured in the present study were the human endothelial cells ECV 
and the human adult glioblastoma cell line (grade IV) SF268 obtained from Jonathan 
Becker Laboratory.  Human endothelial cells ECV were cultured in RPMI-1640 
supplemented with 10% Fetal Bovine Serum (FBS) and 100U/µl of 
penicillin/streptomycin and human adult glioblastoma cell line (grade IV) SF268 
were cultured in Dulbecco`s Modified Eagle Medium (DMEM) supplemented with 
10% Fetal Bovine Serum (FBS) and 100U/µl of penicillin/streptomycin at 37ºC and 
5% CO2 in an incubator.  
 
2.2. Antibodies and reagents  
       The following primary antibodies were used in this study: rabbit polyclonal 
antibody against MMP-9 (Santa Cruz Biotechnology Inc., Europe), rabbit polyclonal 
antibody against pan-AKT (Abcam Inc, Cambridge, UK), rabbit polyclonal antibody 
against AKT1 phosphorylated at T308 (Abcam Inc, Cambridge, UK), rabbit 
polyclonal antibody against MMP-2 (Santa Cruz Biotechnology Inc., Europe), rabbit 
polyclonal antibody against actin (Santa Cruz Biotechnology Inc., Europe) and rabbit 
polyclonal antibody against VEGF (Santa Cruz Biotechnology Inc., Europe). 
Furthermore, anti-rabbit HRP-conjugated secondary antibodies were obtained from 
Promega (Promega Co.,Wisconsin).  
 
2.3. Cell transfection and small interfering RNA 
       Human FlexiTubesiRNA for each of RhoA oligo-1 and oligo-6, RhoC oligo-5 
and oligo-6, Cdc42 oligo-4 and oligo-7, ROCK1 oligo-9 and oligo-10, ROCK2 
oligo-5 and oligo-6, Rac1 oligo-5 and oligo-6, DLC2 oligo-3, RhoG oligo-1, oligo-2 
and oligo-3 were brought from Qiagen (Qiagen, US). Each siRNA had a specific 
target sequence; siRhoA had a target sequence of NM_001664. siRhoC had a target 
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sequence of NM_001042678, NM_00104269 and NM_175744. siRhoG had a target 
sequence of  NM_001665. The siCDC42 had a target sequence of NM_001039802, 
NM_001791 and NM_044472.  siROCK1 had a target sequence of NM_005406. 
siRac1 had a target sequence of NM_006908, NM_018890 and NM_198829. Both 
ECV and SF-268 cells were transfected with the siRNA at a final concentration of 
20µM using a HiPerfect Transfection Reagents obtained from Qiagen (Qiagen, US) 
as mentioned by the manufacturer. After 72 hours, the protein levels in total cell 
lysates were analyzed by western blotting using the appropriate antibodies and the 
blood vessel tubes and sprouts formation was observed by snapshot images upon 
usage of tube formation assay.  
 
2.4. EGF stimulation 
          SF268 cells of 80% confluency were plated in 6-well plates overnight. Cells 
were washed with 2mls of PBS (1X) and then starved with 0.1% BSA in GIBCO 
Leibovitz`s L-15 Medium (1X) Liquid obtained from Invitrogen for 3hours at 37ºC 
in an incubator. After 3 hours, under the laminar flow hood with a time decreasing 
timer the cells were washed directly with PBS (1X) and stimulated with 10ng/ml of 
recombinant human epidermal growth factor (EGF) obtained from Invitrogen for 
specific time intervals. After finishing with the time stimulations, the cells were 
washed with ice cold PBS (1X) and plates were transferred on ice for protein 
extraction.  
 
2.5. Western blots  
         The whole cell lysates were prepared by scraping the cells with Laemmli 
Sample Buffer (LSB) containing 4% SDS, 20% Glycerol, 10% β-Mercaptoethanol, 
0.004% Bromophenol Blue and 0.125M Tris-HCl (pH=6.8). The SDS-PAGE was 
performed under standard and optimized conditions and the proteins were blotted or 
transferred onto a PVDF membrane. Membranes were then blocked either by 5% fat 
free milk or 5% BSA for 2 hours at room temperature depending on the primary 
antibody used. The membranes were then incubated with either primary antibody 
against VEGF (Santa Cruz Biotechnology Inc., Europe) (1:500 dilution), or against 
MMP-2 (Santa Cruz Biotechnology Inc., Europe) (1:700 dilution), or against MMP-
9(Santa Cruz Biotechnology Inc., Europe) (1:750 dilution), or against pan-Akt 
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(Abcam Inc, Cambridge, UK) (1:500 dilution), or against Akt1 phosphorylated at 
T308 (Abcam Inc, Cambridge, UK) (1:750 dilution), or against actin (Santa Cruz 
Biotechnology Inc., Europe) (1:1000) for 2 hours. After that, the membranes were 
washed with 0.5% Tween-20 in PBS for 1 hour at room temperature. The membranes 
were then incubated with secondary antibodies (1:2000 dilutions) for 1 hour at room 
temperature. Blots were developed using chemi-luminescent reagent ECL detection 
kit (GE Healthcare). The results were obtained on an X-ray film (Agfa, Healthcare). 
The levels of expression of proteins were compared by densitometry using the 
ImageJ software and plotted in Excel.  
 
2.6. Tube formation assay  
       The BD Matrigel Basement Membrane Matrix (BD biosciences, Europe) was 
placed at 4ºC the day before plating the cells. 35mm petri dishes were placed inside 
the laminar flow hood on a tray full of ice. All petri dishes, pipettes and pipettes tips 
were pre-cooled also overnight at 4ºC. The dishes were covered with 200µl (without 
any dilution) of BD Matrigel Basement Membrane Matrix (BD biosciences, Europe) 
while holding the tip of pipette upright in the middle of the dish. The dishes were 
closed with their lids and placed inside 140mm petri dishes with paper towel soaked 
with distilled water to ensure an extra humidified chamber. The dishes were then 
placed in the incubator for approximately 1 hour to make sure that gel 
polymerization has taken place. After that, 2x10^5 cells/ml of cells were plated on 
the 35mm petri dish and transfected with siRhoA, siRhoC, siDLC2, siROCK1, 
siCDC42, siROCK2, siRhoG and siRac1. For tube formation analysis, cells were 
captured in RPMI (10% FBS) after each of 24 hours, 48 hours of 72 hours of plating 
using 10X objective. Microscopic images were captured manually using the GrabBee 
software on an inverted phase contrast microscopy. Tube formation assay was 
analyzed and interpreted using the WimTube Software based on different parameters 
such as branching points, tube lengths, tube numbers, loop numbers, areas, 
perimeters, and cell covered area.  
 
2.7. Time lapse movies 
      The BD Matrigel Basement Membrane Matrix (BD biosciences, Europe) was 
placed at 4ºC the day before plating the cells. 35mm petri dishes were placed inside 
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the laminar flow hood on a tray full of ice. All petri dishes, pipettes and pipettes tips 
were pre-cooled also overnight at 4ºC. The dishes were covered with 200µl (without 
any dilution) of BD Matrigel Basement Membrane Matrix (BD biosciences, Europe) 
while holding the tip of pipette upright in the middle of the dish. The dishes were 
closed with their lids and placed inside 140mm petri dishes with paper towel soaked 
with distilled water to ensure an extra humidified chamber. The dishes were then 
placed in the incubator for approximately 1 hour to make sure that gel 
polymerization has taken place. After that, 2x10^5 cells/ml of cells were plated on 
the 35mm petri dish. The area of loops and blood vessel segment length were imaged 
in RPMI or DMEM (10% FBS) media depending on the type of cells (ECV or 
SF268), buffered using HEPES and overlaid with mineral oil and the temperature 
was controlled using a Nikon heating stage which was set at 37ºC. Images were 
collected every 60 seconds using a 10X objective. The blood vessel tubes length and 
area of loops were quantified using the ROI tracker plugin in ImageJ software and 
plotted in Excel.  
 
2.8. Statistical analysis 
        All the results reported represent average values from two independent 
experiments. All error estimates are given as the mean ± standard error of the mean 
(S.E.M). Statistical differences were determined using one-way analysis of variance. 
P values less than 0.05 were considered significant.  
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Chapter Three 
 
Results 
3.1. The effect of Rho GTPases on tube formation  
 RhoA knockdown resulted in significant decrease (approximately by half) for 
both oligos in the total tube length and total tubes number at 24hrs, 48hrs and 72hrs 
(Figure 8B and 8C).  The number of branching points and loops was also decreased 
significantly upon knockdown due to the decrease in the number of tubes formed 
(Figure 8D).  
 
 
   A.    24hrs               48hrs     72hrs  
   Control             
    
  siRhoA (oligo1)        
 
                  siRhoA (oligo6)         
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      B.              
C.  
 
   D.                       
 
Figure 8: Effect of RhoA on Angiogenesis. A) Representative images of vascular endothelial cells plated on BD 
Matrigel before and after knockdown at 24hrs, 48hrs and 72hrs showing that angiogenesis and blood vessels tube 
formation is dependent on RhoA. B) Quantitation of total tube length in pixels of the complete tubular structure 
in endothelial cells before and after knockdown showed that knocking down RhoA decreased significantly the 
total tube length at the three time intervals. C) Quantitation of the total tubes number in endothelial cells before 
and after knockdown revealed that as RhoA was knocked down, the total number of tubes has decreased in 
amount. D) Quantitation of the total branching points which is the point where three or more tubes meet and total 
number of  loops which is the area enclosed by tubular arrangement in endothelial cells before and after 
knockdown showed that RhoA up regulates the number of branching points and loops in angiogenesis.  
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In the previous experiment it was found that RhoA leads to blood vessel tubes 
formation hence as knocking down RhoA took place, the blood vessel tubes was 
decreased. DLC2 or Stard13 is a GTPase activating protein for both RhoA and 
Cdc42 (Khalil et al., 2014). Previous studies have shown that DLC2 (Deleted in 
Liver Cancer 2) suppresses RhoA activity by suppressing cell motility, angiogenesis 
and growth (Leung et al., 2005). Hence knock down of DLC2, increases the blood 
vessels number in endothelial cells. This was proved in the results obtained whereby 
upon inhibiting DLC2 the total number of tubes, total tubes length, branching points 
and number of loops has increased significantly at 24, 48 and 72 hours after siDLC2 
knock down (Figure 9).  
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     C.  
 
 
                  D. 
 
Figure 9: Effect of DLC2 on Angiogenesis. A) Representative images of vascular endothelial cells plated on BD 
Matrigel before and after knockdown at 24hrs, 48hrs and 72hrs showing that DLC2 inhibits angiogenesis. B) 
Quantitation of total tube length in pixels of the complete tubular structure in endothelial cells before and after 
knockdown showed that knocking DLC2 oligo3 increased the total tube length at the three time intervals. C) 
Quantitation of the total tube number in endothelial cells before and after knockdown revealed that as DLC2 
oligo3 was knocked down the total tubes number has increased in amount at the three time intervals. D) 
Quantitation of the total branching points which is the point where three or more tubes meet and total loops which 
is the area enclosed by tubular arrangement in endothelial cells before and after knockdown showed that DLC2 
knockdown up regulates the number of branching points and loops in angiogenesis.   
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DLC2 is a GAP for both RhoA and Cdc42, hence the effect of DLC2 or Stard13 
could be either through RhoA or Cdc42 so next was to knock Cdc42 down using two 
different oligos. Knocking Cdc42 down using two different oligos showed that the 
total number of tubes as well as the length has been decreased significantly in one 
oligo only. In oligo 7, it decreased the first 24hrs then at 48 and 72hrs it didn’t with 
respect to the control (Figure 10B and C). Logically as the total number of tube 
decreases also the number of branching and loops will decrease since no sprouts are 
being formed. Results have shown that the branching points has decreased 
significantly in oligo4 siCdc42 (Figure 10D).  
A.                 24hrs                    48hrs           72hrs  
        Control                
siCdc42 (oligo4)             
siCdc42 (oligo7)              
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      C. 
 
                        
 D. 
 
Figure 10: Effect of Cdc42 on Angiogenesis. A) Representative images of vascular endothelial cells plated on 
BD Matrigel before and after knockdown at 24hrs, 48hrs and 72hrs showing that Cdc42 up regulated 
angiogenesis significantly in oligo4. B) Quantitation of total tube length in pixels of the complete tubular 
structure in endothelial cells before and after knockdown showed that knocking Cdc42 oligo4 decreased the total 
tube length at the three time intervals however in oligo7 it decreased the tube formation for the first 24hrs then it 
stabilized the formation at 48 and 72 hrs. C) Quantitation of the total tube number in endothelial cells before and 
after knockdown revealed that as Cdc42 oligo4 was knocked down the total tube number has decreased in 
amount. D) Quantitation of the total branching points which is the point where three or more tubes meet and total 
loops which is the area enclosed by tubular arrangement in endothelial cells before and after knockdown showed 
that Cdc42 up regulates the number of branching points and loops in angiogenesis.  
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The effect of Cdc42 on tube formation doesn’t seem as pronounced as that of RhoA. 
Other downstream effectors from RhoA were studied. ROCK1 knockdown resulted 
in significant decrease in the total tube length in oligo 9 at 24, 48 and 72 hours 
(Figure 11B). The tubes number in addition to the branching points at each of the 
three time intervals showed a significant decrease in oligo 9 at the three time 
intervals with respect to the control however oligo 10 didn’t show any significant 
decrease (Figure 11C and D respectively).  
 
A.           24hrs         48hrs       72hrs 
     Control              
 siROCK1 (oligo9)        
siROCK1 (oligo10)        
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   C. 
           
D.  
                   
 
Figure 11: Effect of ROCK1 on Angiogenesis. A) Representative images of vascular endothelial cells plated on 
BD Matrigel before and after knockdown at 24hrs, 48hrs and 72hrs. B) Quantitation of total tube length in pixels 
of the complete tubular structure in endothelial cells before and after knockdown showed that knocking ROCK1 
in oligo9 decreased the total tube length at the three time intervals. C) Quantitation of the total tube number in 
endothelial cells before and after knockdown revealed that as ROCK1 was knocked down the total tubes number 
has decreased in amount at the three time intervals in oligo9. D) Quantitation of the total branching points which 
is the point where three or more tubes meet and total loops which is the area enclosed by tubular arrangement in 
endothelial cells before and after knockdown showed that ROCK1 knockdown down regulates the number of 
branching points and loops in angiogenesis.   
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ROCK2 knockdown resulted in significant decrease in the total tube length in both 
oligos at three time intervals (Figure 12B). The tubes number decreased significantly 
with respect to the control at 24 hours however at 48hours and 72hours they started 
to stabilize with respect to the control. The branching points at each of the three time 
intervals showed a decrease also (Figure 12C and D respectively).  
A.                 24hrs                             48hrs             72hrs 
     Control              
siROCK2 (oligo5)        
siROCK2 (oligo6)            
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   C. 
 
  D. 
 
Figure 12: Effect of ROCK2 on Angiogenesis. A) Representative images of vascular endothelial cells plated on 
BD Matrigel before and after knockdown at 24hrs, 48hrs and 72hrs showing that angiogenesis is dependent on 
ROCK2. B) Quantitation of total tube length in pixels of the complete tubular structure in endothelial cells before 
and after knockdown showed that knocking ROCK1 in both oligos decreased the total tube length at the three 
time intervals. C) Quantitation of the total tube number in endothelial cells before and after knockdown revealed 
that as ROCK2 was knocked down the total tubes number has decreased in amount at 24hours then it started to 
stabilize at 48 and 72 hours. D) Quantitation of the total branching points which is the point where three or more 
tubes meet and total loops which is the area enclosed by tubular arrangement in endothelial cells before and after 
knockdown showed that ROCK2 knockdown down reduce the number of branching points and loops in 
angiogenesis.   
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ROCK2 had a more pronounced effect than ROCK1 on tube formation and ROCK2 
which is a downstream effector of RhoA increases angiogenesis. Other Rho isoforms 
were also studied such as RhoG protein. RhoG is a novel isoform of Rho proteins 
however a little is known about its downstream effectors. Next we were interested in 
elucidating the downstream effectors responsible for angiogenesis or tube formation.  
RhoG knockdown resulted in significant decrease in the total tube length using the 
three oligos at the three different time intervals (Figure 13B). The number of tubes in 
addition to number of loops and branching points at each of the three time intervals 
showed a decrease also (Figure 13C and D). Hence angiogenesis and blood vessel 
tube formation is RhoG dependent in vascular endothelial cells.  
 
A.               24hrs                48hrs      72hrs  
               Control                  
              siRhoG (Oligo1)     
              siRhoG (Oligo2)     
                       siRhoG (Oligo3)      
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B. 
 
 
  C. 
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 D. 
        
 
Figure 13: Effect of RhoG on Angiogenesis. A) Representative images of vascular endothelial cells plated on 
BD Matrigel before and after knockdown at 24hrs, 48hrs and 72hrs showing that angiogenesis is dependent on 
RhoG protein. B) Quantitation of total tube length in pixels of the complete tubular structure in endothelial cells 
before and after knockdown showed that knocking RhoG in all oligos decreased the total tube length at the three 
time intervals. C) Quantitation of the total tube number in endothelial cells before and after knockdown revealed 
that as RhoG was knocked down, the total tubes number has decreased in amount. D) Quantitation of the total 
branching points which is the point where three or more tubes meet and total loops which is the area enclosed by 
tubular arrangement in endothelial cells before and after knockdown showed that RhoG protein up regulates the 
number of branching points and loops in angiogenesis.  
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Knocking RhoC down showed that in oligo5, the total tubes number and length has 
increased for the first 24hrs then it started to decrease after 48 and 72hrs. However 
upon using siRhoC oligo6 the total tubes number and length has drastically and 
significantly decreased at all of the 3 different time intervals (Figure 14B and C). The 
branching points and number of loops has increased in siRhoC oligo5 at the first 
24hrs which is logically since the total number of tubes has increased then it started 
to significantly decrease at 48 and 72 hrs (Figure 14D).  
A.            24hrs   48hrs             72hrs  
         Control            
   siRhoC (oligo5)          
   siRhoC (oligo6)          
    
B. 
 
 
0 
1000 
2000 
3000 
4000 
5000 
6000 
7000 
8000 
To
ta
l T
u
b
e
 L
e
n
gt
h
 (
p
ix
e
ls
) 
36 
 
C. 
 
             D. 
 
Figure 14: Effect of RhoC on Angiogenesis. A) Representative images of vascular endothelial cells plated on 
BD Matrigel before and after knockdown at 24hrs, 48hrs and 72hrs showing that RhoC up regulates angiogenesis 
in time dependent manner. B) Quantitation of total tube length in pixels of the complete tubular structure in 
endothelial cells before and after knockdown showed that knocking RhoC oligo5 has increased the length of tube 
for the first 24hrs and then decreased the length at 48hrs and 72hrs. C) Quantitation of the total tubes number in 
endothelial cells before and after knockdown revealed that as RhoC was knocked down the total tube number has 
increased for the first 24hrs in oligo5 then is has decreased at 48 and 72hrs. D) Quantitation of the total branching 
points which is the point where three or more tubes meet and total loops which is the area enclosed by tubular 
arrangement in endothelial cells before and after knockdown showed that as the number of tubes and length 
increase or decrease the number of branching points and loops decrease or increase in proportional manner.  
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Rac1knockdown resulted in significant decrease in the total tube length and total 
tubes number at 24hrs, 48hrs and 72hrs specifically oligo5 (Figure 15B and 15C 
respectively).  The number of branching points and loops was also decreased upon 
knockdown due to the decrease in the number of blood vessels tube formation 
(Figure 15D).  
 
A.                 24hrs                               48hrs                 72hrs  
Control             
siRac1 (oligo5)      
siRac1 (oligo6)       
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C. 
 
  D. 
                
 
Figure 15: Effect of Rac1 on Angiogenesis. A) Representative images of vascular endothelial cells plated on 
BD Matrigel before and after knockdown at 24hrs, 48hrs and 72hrs showing that Rac1 up regulates angiogenesis. 
B) Quantitation of total tube length in pixels of the complete tubular structure in endothelial cells before and after 
knockdown showed that knocking Rac1 decreased the total tube length at the three time intervals. C) Quantitation 
of the total tube number in endothelial cells before and after knockdown revealed that as Rac1 was knocked down 
the total tubes number has decreased in amount. D) Quantitation of the total branching points which is the point 
where three or more tubes meet and total loops which is the area enclosed by tubular arrangement in endothelial 
cells before and after knockdown showed that Rac1 up regulates the number of branching points and loops in 
angiogenesis.  
Knocking RhoG down reduced tube formation in vascular endothelial cells in 
addition RhoC and Rac1 had a less pronounced effect on angiogenesis.  
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3.2. Effect of RhoA on VEGF levels of expression  
In the second part, the effect of Rho GTPases as well as PI3K on VEGF and 
MMPs especially MMP-2 and MMP-9 levels of expression and secretion was studied 
in Astrocytoma cells. Knocking RhoA down in Astrocytoma cells using two different 
oligos and detecting the level of expression of VEGF using a western blot has 
showed that the expression level has almost decreased significantly approximately by 
40% (Figure 16). Hence the level of expression of VEGF in Astrocytoma cancer 
cells is RhoA dependent.  
A.                                                            B. 
 
Figure 16: Effect of RhoA on VEGF Levels of Expression. A) Astrocytoma cells were depleted of RhoA and 
western blot was performed to detect the level of VEGF expression. B) Quantitation results showing the effect of 
RhoA knockdown on level of VEGF expression. The level of expression of VEGF has decreased once the cells 
are depleted out of RhoA. n=2 and data are mean ± S.E.M. * shows that the results are significant.  
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3.3. Effect of RhoA on MMP-2 levels of expression  
Knocking RhoA down in Astrocytoma cells using two different oligos and 
detecting the level of expression of MMP-2 using a western blot has showed that the 
expression level has almost decreased significantly approximately by 50% (Figure 
17). Hence the level of expression of MMP-2 in Astrocytoma cancer cells is also 
RhoA dependent.  
 
Figure 17: Effect of RhoA on MMP-2 Levels of Expression. A-B) Astrocytoma cells were depleted of RhoA 
and western blot was performed. C) Quantitation results showing the effect of RhoA knockdown on level of 
MMP-2 expression. The level of expression of MMP-2 has decreased once the cells are depleted out of RhoA. 
n=2 and data are mean ± S.E.M. * shows that the results are significant.  
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 3.4. Effect of RhoC on VEGF levels of expression 
Knocking RhoC down in Astrocytoma cells using two different oligos and 
detecting the level of expression of VEGF using a western blot has showed that the 
expression level has almost decreased significantly approximately by 25% (Figure 
18). The levels of expression of VEGF after knocking RhoC down were not as that 
as pronounced when the level of expression of VEGF was detected after knocking 
RhoA down previously (Figure 16). Same for the previous part, the effect of RhoA 
on tube formation in endothelial cells was more pronounced than RhoC in vascular 
endothelial cells.  
 
Figure 18: Effect of RhoC on VEGF Levels of Expression. A) Astrocytoma cells were depleted of RhoC and 
western blot was performed. B) Quantitation results showing the effect of RhoC knockdown on level of VEGF 
expression. The level of expression of VEGF has decreased once the cells are depleted out of RhoC 
approximately by 25%. n=2 and data are mean ± S.E.M. * shows that the results are significant. 
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3.5. Effect of ROCK2 on MMP-2 levels of expression 
Knocking ROCK2 down in Astrocytoma cells and detecting the level of 
expression of MMP-2 using a western blot has showed that the expression level has 
almost decreased significantly and drastically approximately by 70% (Figure 19). 
ROCK2 which is a downstream effector from RhoA had a very pronounced effect on 
MMPs level of expression in Astrocytoma cells.  
 
Figure 19: Effect of ROCK2 on MMP-2 Levels of Expression. A) Astrocytoma cells were depleted of ROCK2 
and western blot was performed. B) Quantitation results showing the effect of ROCK2 knockdown on level of 
MMP2 expression. The level of expression of MMP2 has decreased drastically once the cells are depleted out of 
ROCK2 approximately by 70%. n=2 and data are mean ± S.E.M. * shows that the results are significant. 
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3.6. Effect of starvation on VEGF, MMP-2 and MMP-9 expression 
levels  
         Tumor cells release VEGF and MMPs in response to starvation or hypoxia. 
Hence starvation of Astrocytoma cells was done in order to look at the increase in 
VEGF and MMPs level of expression. Astrocytoma cells were starved for 3hrs, 
24hrs and 48hrs and then the level of expression of VEGF, MMP-2 and MMP-9 was 
detected by western blot. The results below showed that the level of VEGF 
expression is increasing as the cells are starved for more period of time. The level of 
VEGF has increased significantly by approximately 1 fold from 3hrs to 48hrs after 
starvation (Figure 20).  
        A. 
 
       B. 
 
Figure 20: Level of Expression of VEGF after Different Times of Starvation. Astrocytoma cells were starved 
with L15 medium for 3hrs, 24hrs and 48hrs. A) Western blots showing the level of expression of VEGF after 
different times of starvation. B) Bar graph quantitation of the results obtained showing that the levels of secretion 
of VEGF at 48hrs is the highest. It almost increased by approximately one fold with respect to 3hrs of starvation. 
n=2 and data are mean ± S.E.M. * shows that the results are significant. 
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The same experiment was done however this time we wanted to assess the levels of 
expression of MMP-2. The results below showed that upon starving the Astrocytoma 
cells for 3hrs, 24hrs and 48 hours the level of MMP-2 expression was significantly 
highest at 48hrs after starvation with approximately 0.6 folds increase compared with 
3 hours of starvation (Figure 21).  
 
  A. 
 
 
                       B. 
 
Figure 21: Level of Expression of MMP-2 after Different Times of Starvation. SF268 cells were starved with 
L15 medium for 3hrs, 24hrs and 48hrs. A) Western blots showing the level of expression of MMP-2 after 
different times of starvation. B) Bar graph quantitation of the results obtained showing that the levels of secretion 
of MMP-2 at 48hrs is the highest. It almost increased by approximately 0.6 folds with respect to 3hrs of 
starvation. n=2 and data are mean ± S.E.M. * shows that the results are significant. ** shows results are not 
significant.  
 
 
45 
 
The levels of expression of MMP-9 were detected using the same experiment as the 
ones performed before. The results below showed that as the cells are starved for 
more time the levels of expression of MMP-9 are significantly increasing (Figure 
22). The levels of expression of MMP-9 at 48 hours of starvation increased by 
approximately 1.5 fold with respect to 3 hours of starvation.  
 
     A. 
 
          B. 
 
Figure 22: Level of Expression of MMP-9 after Different Times of Starvation. SF268 cells were starved with 
L15 medium for 3hrs, 24hrs and 48hrs. A) Western blots showing the level of expression of MMP-9 after 
different times of starvation. B) Bar graph quantitation of the results obtained showing that the levels of secretion 
of MMP-9 at 48hrs is the highest. It almost increased by approximately the double with respect to 3hrs of 
starvation. n=2 and data are mean ± S.E.M. * shows that the results are significant 
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3.7. Effect of starvation and Rho GTPases knockdown on VEGF 
level of expression 
      In the previous section SF268 were only starved at 3hrs, 24hrs and 48hrs 
however in this part knock down took place because we wanted to figure out the 
effect of Rho GTPases knockdown specifically RhoA on Astrocytoma cells upon 
starvation. Astrocytoma cells were knocked down with Rho GTPases for 72hrs and 
cells were starved with L15 medium for 3hrs, 24hrs and 48hrs. As knockdown is 
performed with starvation the level of expression of VEGF is decreasing 
significantly at the three time intervals of starvation (Figure 23). Hence the increase 
in VEGF levels of expression is RhoA dependent.   
 A. 
 
    B. 
 
Figure 23: Level of Expression of VEGF after Different Times of Starvation and siRhoA Knockdown. 
SF268 cells were knocked down with siRhoA and starved with L15 medium for 3hrs, 24hrs and 48hrs. A) 
Western blots showing the level of expression of VEGF after different times of starvation and knockdown. B) Bar 
graph quantitation of the results obtained showing that upon starvation and knockdown the level of VEGF is 
decreasing. The lowest level of VEGF secretion was upon knockdown and starvation for 3hrs. n=2 and data are 
mean ± S.E.M. * shows results are significant.  
47 
 
3.8. Effect of EGF stimulation on p-Akt levels of secretion  
To distinguish between the increase in the level of expression and the level of 
secretion of VEGF and MMPs, Astrocytoma were stimulated with epidermal growth 
factor (EGF) for short stimulation times to detect the increase in the level of 
secretion. Astrocytoma cells were stimulated with epidermal growth factors for short 
time intervals and the level of secretion of p-Akt was detected by western blot. High 
levels of p-Akt are secreted after 0 minutes of stimulation.  The level of expression 
of p-Akt at 3 minutes has increased by approximately 1.5 folds and at 5 minutes it 
increased approximately by 2.4 folds compared to 0 minutes (Figure 24). Hence 
when Astrocytoma cells are stimulated with EGF, an activation of the PI3K pathway 
is observed.  
      A. 
 
     B. 
               
Figure 24: Level of Secretion of p-Akt after EGF Stimulation. SF268 cells were stimulated with EGF at 
different short time intervals. A) Western blots showing the level of secretion of phospho-Akt after EGF 
stimulation for showet period of time in Astrocytoma cells B) Bar graph quantitation of the results showing that 
at 3 minutes the signal level of p-Akt has increased by 1.5 folds however at 5 minutes it was more by increasing 
approximately by 2.4 folds compared to 0 minutes. n=2 and data are mean ± S.E.M. * shows that the results are 
significant.  
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3.9. Effect of EGF stimulation on VEGF levels of secretion  
Astrocytoma cells were stimulated with epidermal growth factors for short time 
intervals and the levels of secretion of VEGF was detected by western blot. Results 
have showen that as the cells are stimulated with EGF the levels of secretion of 
VEGF were almost the same with no significant difference observed (Figure 25).  
The levels of secretion of VEGF were stable even when compared to 0 minutes. 
Hence when Astrocytoma cells are stimulated with EGF the total levels of VEGF 
were not changed.  
 
A. 
 
   B. 
 
Figure 25: Level of Secretion of VEGF after EGF Stimulation. SF268 cells were stimulated with EGF at 
different time intervals. A) Western blots showing the level of secretion of VEGF after EGF stimulation in 
Astrocytoma cells presenting that the levels of secretion were not changed. B) Bar graph quantitation of the 
results showing that as the Astrocytoma cells are stimulated with EGF the levels of secretion of VEGF were not 
changed. n=2 and data are mean ± S.E.M.                               
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Chapter Four 
 
Discussion 
 Angiogenesis is the ability of existing blood vessels to form new tubes (Sang, 
1998).  Studies have emphasized that the role of vascular endothelial cells is 
regulated by PI3K, vascular endothelial growth factor (VEGF) and 
metalloproteinases (Huo et al., 2002). It was also reported that angiogenesis is 
mediated by the Rho GTPase family of proteins in ECV through the secretion of 
VEGF and MMPs.  
 Our first objective was to study the effect of Rho GTPases on vascular 
endothelial cells. In ECV cells, the knock down of RhoA reduced significantly the 
blood tubes formation (Figure 8) especially that tubes number and length in addition 
to the branching points were decreasing. STARD13 is a GAP for RhoA and Cdc42 in 
addition it suppresses RhoA activity by inhibiting the formation of angiogenesis 
(Leung et al., 2005). In our results upon knocking down DLC2 the tube vessel 
formation has increased, hence this proves what was established in literature as 
DLC2 being an inhibitor of angiogenesis (Figure 9). Since DLC2 or STARD13 is 
GAP for both RhoA and Cdc42 hence the effect could also be through Cdc42 that’s 
why it was essential to deplete endothelial cells out of Cdc42. Cdc42 had an effect in 
one oligo but not in the other one on tube formation. The effect of Cdc42 also 
doesn’t seem to be as pronounced as that of RhoA this can be due to several reasons 
either the different levels of inhibition on RhoA and Cdc42 in these cells by DLC2, 
the different levels of knockdown of RhoA and Cdc42 by the oligos or the different 
effects of Cdc42 and RhoA on tube formation. These reasons can be solved by 
performing western blots to detect levels of knockdowns of Cdc42 and RhoA in 
these cells by these oligos, performing Cdc42 and RhoA pull down assays in control 
cells and cells over expressing DLC2 or transfected with siDLC2 and finally by 
performing rescue experiments in the DLC2 knockdown cells over expressing either 
active Cdc42 or RhoA constructs and looking at the effect on tube formation. 
Downstream effectors of RhoA were also studied and ROCK2 showed to inhibit tube 
formation in a more pronounced manner (Figure 12) than that of ROCK1 (Figure 
11). RhoG has an effect on tube formation reduction same for RhoC however RhoC 
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showed a less efficient effect on tube formation compared to the control (Figure 14). 
Although most of the proteins showed once knocked down reduction in tube 
formation however an important factor should always be remembered is that this 
reduction could also be to due to cell death after 48 and 72 hours of transfection. To 
ensure that cell death is not the case, vascular endothelial cells should be knocked 
down later on with the same proteins that were used in tube formation assay and then 
perform a western blot to detect the level of expression of each protein that was 
knocked down.  
 In the second part, the effect of Rho GTPases on VEGF and MMPs level of 
expression as well as secretion in response to starvation and EGF stimulation 
respectively was studied. RhoA had a more pronounced effect (Figure 16) than that 
of RhoC (Figure 18) on VEGF levels on expression in Astrocytoma cells when 
knocked down. Same results were obtained in vascular endothelial cells in which 
RhoA had a more pronounced effect than RhoC in tube formation. Results ensure 
that the VEGF expression is more RhoA dependant. Data obtained showed a 
significant decrease in the level of expression when Astrocytoma cells were knocked 
out from ROCK2 which is a downstream effector from RhoA (Figure 19).  
Since tumor cells secrete VEGF and MMPs in response to hypoxia we 
wanted to mimic the physiological conditions by starving the Astrocytoma cells at 
different times to look for this basal increase in VEGF, MMP-2, and MMP-9 levels 
of expression. The results showed that upon starving the Astrocytoma cells for a long 
period of time the level of secretion of VEGF and metalloproteinases was increasing 
(Figures 20, 21 and 22). The results also validated that RhoA clearly played a role in 
VEGF secretion downstream from starvation (Figure 23). Hence the increase in 
VEGF was also RhoA dependent.  
Astrocytoma cells were stimulated with EGF for short stimulation times to 
detect the increase in level of secretion of p-Akt and VEGF. When Astrocytoma cells 
were stimulated with EGF, the PI3K pathway was significantly activated (Figure 24) 
especially that when EGF bind to EGF receptor on the plasma membrane it leads to 
the PI3K activation and then PI3K through the production of PIP3 regulates the Rho 
GTPase family of proteins. However when Astrocytoma cells are stimulated with 
EGF for short stimulation times the level of secretion for VEGF possessed no 
significant change at each time intervals. To mention the effect of EGF stimulation 
on VEGF and p-Akt levels of secretion the cells should be starved, stimulated with 
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EGF for longer times and level of expression of VEGF and MMPs should be 
detected by RT-PCR and western blot. Also Astrocytoma cells should be starved, 
stimulated with EGF for longer times and level of secretion of VEGF and MMPs 
should be detected by ELISA and western blot.  
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Chapter Five 
 
Conclusion 
 Rho GTPases has played a crucial role in angiogenesis signaling in vascular 
endothelial. This study showed that Angiogenesis is RhoA, RhoG and RhoC 
dependant. DLC2 is an inhibitor of tube formation or angiogenesis signal 
transduction. ROCK2 has a more pronounced effect than ROCK1 on angiogenesis. 
Astrocytoma cells are regulated by VEGF, MMP-2 and MMP-9 expression after 
starvation. Rho GTPases especially RhoA and RhoC regulates the level of expression 
of VEGF and MMPs in Astrocytoma cells. In conclusion, this study will clarify the 
effect of Rho GTPases in Astrocytoma cells and vascular endothelial cells on VEGF 
and MMPs.  
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